| Product Code: ETC8836766 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Dhaval Chaurasia | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
The CNV market in the Philippines primarily revolves around age-related macular degeneration (AMD) and other retinal disorders. Anti-VEGF therapies dominate treatment options, with growing demand as the elderly population rises. Access to ophthalmologic care and diagnostic imaging is increasing, supporting market development in both public and private healthcare sectors.
The CNV market is expanding due to the rising prevalence of age-related macular degeneration (AMD) among the aging population. Increased screening, diagnosis, and availability of anti-VEGF therapies have boosted market growth. Medical tourism and partnerships with global pharmaceutical firms further support the sector`s advancement.
Treatment for CNV is challenged by the limited availability of specialized ophthalmologic care, particularly in rural areas. High costs of anti-VEGF therapies and diagnostic imaging systems place them out of reach for many patients. Lack of public health insurance coverage for long-term treatments also hinders access. Awareness among general practitioners is low, leading to delayed referrals and diagnosis.
The CNV market offers long-term opportunities with the aging population and increasing cases of age-related macular degeneration. Investments in biologics, diagnostic imaging services, and partnerships with ophthalmology centers can provide access to this growing therapeutic area. Research collaboration in ocular drug delivery systems is another frontier for innovation.
Government healthcare policies under the Department of Health and the Philippine Health Insurance Corporation (PhilHealth) support treatment for CNV-related conditions, particularly age-related macular degeneration (AMD). Access to anti-VEGF therapies, although limited due to high cost, is gradually being supported through public hospital formularies and generic drug inclusion. The FDA regulates the approval of ophthalmologic treatments, while public-private partnerships focus on improving early diagnosis.
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Philippines CNV (Choroidal NeoVascularization) Market Overview |
3.1 Philippines Country Macro Economic Indicators |
3.2 Philippines CNV (Choroidal NeoVascularization) Market Revenues & Volume, 2021 & 2031F |
3.3 Philippines CNV (Choroidal NeoVascularization) Market - Industry Life Cycle |
3.4 Philippines CNV (Choroidal NeoVascularization) Market - Porter's Five Forces |
3.5 Philippines CNV (Choroidal NeoVascularization) Market Revenues & Volume Share, By Diagnosis, 2021 & 2031F |
3.6 Philippines CNV (Choroidal NeoVascularization) Market Revenues & Volume Share, By Treatment, 2021 & 2031F |
3.7 Philippines CNV (Choroidal NeoVascularization) Market Revenues & Volume Share, By End-Users, 2021 & 2031F |
3.8 Philippines CNV (Choroidal NeoVascularization) Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F |
4 Philippines CNV (Choroidal NeoVascularization) Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of age-related macular degeneration (AMD) in the Philippines |
4.2.2 Rising awareness about eye health and early detection of CNV |
4.2.3 Growing adoption of advanced diagnostic technologies for CNV diagnosis |
4.3 Market Restraints |
4.3.1 High cost associated with CNV treatments and therapies |
4.3.2 Limited access to specialized eye care services in remote areas of the Philippines |
4.3.3 Stringent regulatory requirements for approval of CNV treatment options |
5 Philippines CNV (Choroidal NeoVascularization) Market Trends |
6 Philippines CNV (Choroidal NeoVascularization) Market, By Types |
6.1 Philippines CNV (Choroidal NeoVascularization) Market, By Diagnosis |
6.1.1 Overview and Analysis |
6.1.2 Philippines CNV (Choroidal NeoVascularization) Market Revenues & Volume, By Diagnosis, 2021- 2031F |
6.1.3 Philippines CNV (Choroidal NeoVascularization) Market Revenues & Volume, By Fluorescein AngiographyOptical Coherence Tomography, 2021- 2031F |
6.1.4 Philippines CNV (Choroidal NeoVascularization) Market Revenues & Volume, By Others, 2021- 2031F |
6.2 Philippines CNV (Choroidal NeoVascularization) Market, By Treatment |
6.2.1 Overview and Analysis |
6.2.2 Philippines CNV (Choroidal NeoVascularization) Market Revenues & Volume, By Anti-VEGF, 2021- 2031F |
6.2.3 Philippines CNV (Choroidal NeoVascularization) Market Revenues & Volume, By Photodynamic Therapy, 2021- 2031F |
6.2.4 Philippines CNV (Choroidal NeoVascularization) Market Revenues & Volume, By Thermal Laser, 2021- 2031F |
6.2.5 Philippines CNV (Choroidal NeoVascularization) Market Revenues & Volume, By Others, 2021- 2031F |
6.3 Philippines CNV (Choroidal NeoVascularization) Market, By End-Users |
6.3.1 Overview and Analysis |
6.3.2 Philippines CNV (Choroidal NeoVascularization) Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.3.3 Philippines CNV (Choroidal NeoVascularization) Market Revenues & Volume, By Homecare, 2021- 2031F |
6.3.4 Philippines CNV (Choroidal NeoVascularization) Market Revenues & Volume, By Specialty Clinics, 2021- 2031F |
6.3.5 Philippines CNV (Choroidal NeoVascularization) Market Revenues & Volume, By Others, 2021- 2031F |
6.4 Philippines CNV (Choroidal NeoVascularization) Market, By Distribution Channel |
6.4.1 Overview and Analysis |
6.4.2 Philippines CNV (Choroidal NeoVascularization) Market Revenues & Volume, By Hospital Pharmacy, 2021- 2031F |
6.4.3 Philippines CNV (Choroidal NeoVascularization) Market Revenues & Volume, By Retail Pharmacy, 2021- 2031F |
6.4.4 Philippines CNV (Choroidal NeoVascularization) Market Revenues & Volume, By online Pharmacies, 2021- 2031F |
6.4.5 Philippines CNV (Choroidal NeoVascularization) Market Revenues & Volume, By Others, 2021- 2031F |
7 Philippines CNV (Choroidal NeoVascularization) Market Import-Export Trade Statistics |
7.1 Philippines CNV (Choroidal NeoVascularization) Market Export to Major Countries |
7.2 Philippines CNV (Choroidal NeoVascularization) Market Imports from Major Countries |
8 Philippines CNV (Choroidal NeoVascularization) Market Key Performance Indicators |
8.1 Number of ophthalmologists specializing in CNV treatment in the Philippines |
8.2 Adoption rate of advanced CNV diagnostic technologies in eye care facilities |
8.3 Percentage of CNV patients receiving timely treatment and follow-up care |
8.4 Rate of successful outcomes in CNV treatment procedures |
8.5 Patient satisfaction levels with CNV treatment services |
9 Philippines CNV (Choroidal NeoVascularization) Market - Opportunity Assessment |
9.1 Philippines CNV (Choroidal NeoVascularization) Market Opportunity Assessment, By Diagnosis, 2021 & 2031F |
9.2 Philippines CNV (Choroidal NeoVascularization) Market Opportunity Assessment, By Treatment, 2021 & 2031F |
9.3 Philippines CNV (Choroidal NeoVascularization) Market Opportunity Assessment, By End-Users, 2021 & 2031F |
9.4 Philippines CNV (Choroidal NeoVascularization) Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F |
10 Philippines CNV (Choroidal NeoVascularization) Market - Competitive Landscape |
10.1 Philippines CNV (Choroidal NeoVascularization) Market Revenue Share, By Companies, 2024 |
10.2 Philippines CNV (Choroidal NeoVascularization) Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here